Neurology News and Research

Latest Neurology News and Research

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

Valeant Pharmaceuticals International prices $400M of 7.625% senior unsecured notes due 2020

Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.

7 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Mobile compression device effective in preventing blood clots after hip replacement surgery

A mobile compression device is as effective as medication at preventing the formation of blood clots after hip replacement surgery but provides greater patient safety, according to a study in the March issue of the Journal of Bone & Joint Surgery.

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.

6 Apr 2010

Scientists develop low-cost behavioral assessment to detect progression of MCI

Your brain's capacity for information is a reliable predictor of Alzheimer's disease and can be cheaply and easily tested, according to scientists.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Therapeutic hypothermia helps save marathon cardiac arrest victim

Jay Yim, 21, had worked on improving his fitness since age 15. In preparation for this year's Los Angeles Marathon on March 21, the University of Southern California pre-med student had been training with a marathon club and regularly did 10-mile runs on his own.

3 Apr 2010

NewYork-Presbyterian Hospital installs high-tech imaging systems for heart and vascular surgeries

In a move that could change the way many patients undergo surgery, NewYork-Presbyterian Hospital has installed five state-of-the-art Siemens Artis zeego- medical imaging systems that provide faster, more accurate 3-D images of the body with a quality never before attainable.

3 Apr 2010

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

2 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Using new one-of-a-kind "mouse models" that promise to have a significant impact on future Parkinson's disease research, Mount Sinai School of Medicine researchers are among the first to discover how mutations in a gene called LRRK2 may cause inherited (or "familial") Parkinson's disease, the most common form of the disease. The study, published in The Journal of Neuroscience, is the first in vivo evidence that LRRK2 regulates dopamine transmission and controls motor performance, and that the mutation of LRRK2 eliminates the normal function of LRRK2, leading to Parkinson's disease.

1 Apr 2010

Researchers develop experimental protocol to detect age-related memory disorders

By studying the aging of memory in the mouse, researchers in the Laboratoire Neurobiologie des Processus Adaptatifs have developed an experimental protocol that can detect age-related memory deficits at an early stage. They have shown that even at 10 months, which corresponds to a third of their life expectancy, some mice present with age-related memory disorders.

1 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Funds raised at CASMA's spring conference to benefit The Montréal Children's Hospital

Mondial Assistance and the Computerized Airline Sales and Marketing Association announced today that a fundraiser held during a reception at CASMA's spring conference in Montréal raised enough money to purchase a saturation/end tidal carbon dioxide monitor for the Department of Anesthesia at The Montréal Children's Hospital.

31 Mar 2010

Loss of physical, psychological function after traumatic brain injury not related to injuries in brain structures

It has been thought that the loss of physical and psychological function after traumatic brain injury is closely related to injuries in brain structures. However, in the current edition of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[12]: 199-205), Rainer Scheid and D. Yves von Cramon conclude that this is not the case.

31 Mar 2010

Neurology News and Research

Latest Neurology News and Research

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

Valeant Pharmaceuticals International prices $400M of 7.625% senior unsecured notes due 2020

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

Mobile compression device effective in preventing blood clots after hip replacement surgery

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

Scientists develop low-cost behavioral assessment to detect progression of MCI

Dalfampridine drug for multiple sclerosis now available in the U.S.

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Clinical utility and pharmacological action of MN-166 in treatment of MS

Therapeutic hypothermia helps save marathon cardiac arrest victim

NewYork-Presbyterian Hospital installs high-tech imaging systems for heart and vascular surgeries

"Mouse model" study finds LRRK2 gene mutation may cause inherited Parkinson's disease

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Researchers develop experimental protocol to detect age-related memory disorders

RXi Pharmaceuticals reports net loss of 28% for 2009

Funds raised at CASMA's spring conference to benefit The Montréal Children's Hospital

Loss of physical, psychological function after traumatic brain injury not related to injuries in brain structures

Neuroscience - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Neurology News and Research

Latest Neurology News and Research

Neuroscience - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in